Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients
Not Applicable
Completed
- Conditions
- Patient
- Interventions
- Procedure: Hyperspectral Endoscopy (HySE)Device: White Light Endoscopy (WLE)
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT04172493
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy
Not Applicable
Completed
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmChemotherapy-Induced Peripheral Neuropathy
- Interventions
- Behavioral: Whole Body Vibration
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT04170075
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
Phase 1
Recruiting
- Conditions
- Rectal AdenocarcinomaStage IIA Rectal Cancer AJCC V8Stage IIB Rectal Cancer AJCC V8Stage III Rectal Cancer AJCC V8Stage IIIA Rectal Cancer AJCC V8Stage IIIB Rectal Cancer AJCC V8Stage IIIC Rectal Cancer AJCC V8
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyDrug: Trifluridine and Tipiracil Hydrochloride
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT04104139
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Early Phase 1
Recruiting
- Conditions
- Unresectable Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8
- Interventions
- Drug: AzenosertibDrug: SaruparibBiological: TremelimumabDrug: OlaparibDrug: CobimetinibDrug: Onvansertib
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT04005690
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Stage IA1 Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Extensive Stage Lung Small Cell CarcinomaStage IIIA Lung Cancer AJCC v8Limited Stage Lung Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8
- Interventions
- Other: Questionnaire AdministrationDevice: Tumor Treating Fields Therapy
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT03995667
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Glucarpidase After High-Dose Methotrexate in Patients with Osteosarcoma
Early Phase 1
Active, not recruiting
- Conditions
- Osteosarcoma
- Interventions
- Drug: GlucarpidaseOther: Quality-of-Life Assessment
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03960177
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1
Terminated
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Not Applicable
Terminated
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT03812289
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Triple-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Procedure: BiopsyBiological: DurvalumabDrug: CeralasertibDrug: CapivasertibDrug: OlaparibOther: Quality-of-Life AssessmentDrug: Selumetinib
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT03801369
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
GET FIT Prostate: A Randomized Controlled Exercise Trial
Not Applicable
Completed
- Conditions
- Prostate Carcinoma
- Interventions
- Other: StretchingOther: Resistance TrainingOther: Tai Chi
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 335
- Registration Number
- NCT03741335
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath